Ocugen Obtains $6,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=10941d37-9403-442e-8751-4146081c39e3 - Date
12/17/2016 - Company Name
Ocugen - Mailing Address
12635 E Montview Blvd. Aurora, CO 80045 USA - Company Description
Ocugen is advancing two novel biologicals and a marketed drug product as a re-purposed drug under the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway to treat sight threatening ocular disorders. - Website
http://www.ocugen.com - Transaction Type
Venture Equity - Transaction Amount
$6,000,000 - Transaction Round
Series A - Proceeds Purposes
With this funding, we will continue our efforts to aggressively advance the OCU300 program toward an IND submission within a year, bringing this much needed therapy closer to the patients who need it. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
